Published in J Infect Dis on March 01, 1996
A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc Natl Acad Sci U S A (1997) 2.07
Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J Exp Med (1998) 1.98
Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. J Exp Med (1997) 1.61
Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses. J Virol (2001) 1.59
Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor beta1 and beta2 chain expression. J Exp Med (1999) 1.58
Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection. Infect Immun (1997) 1.57
Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect Immun (1997) 1.54
Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect Immun (2001) 1.50
Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat Mater (2010) 1.45
Cholera toxin and heat-labile enterotoxin activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cyclic AMP-dependent pathway. Infect Immun (2002) 1.20
Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract. Infect Immun (2005) 1.15
Role of receptor binding in toxicity, immunogenicity, and adjuvanticity of Escherichia coli heat-labile enterotoxin. Infect Immun (1997) 1.13
Oral tolerance. J Clin Immunol (1998) 1.11
Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection. Infect Immun (2000) 1.09
Alteration of interleukin 4 production results in the inhibition of T helper type 2 cell-dominated inflammatory bowel disease in T cell receptor alpha chain-deficient mice. J Exp Med (1999) 1.08
Protective mucosal immunity to ocular herpes simplex virus type 1 infection in mice by using Escherichia coli heat-labile enterotoxin B subunit as an adjuvant. J Virol (2001) 1.06
Identification of immunodominant antigens of Chlamydia trachomatis using proteome microarrays. Vaccine (2009) 1.05
Recombinant antigen-enterotoxin A2/B chimeric mucosal immunogens differentially enhance antibody responses and B7-dependent costimulation of CD4(+) T cells. Infect Immun (2001) 1.02
Immunogenicity of the B monomer of Escherichia coli heat-labile toxin expressed on the surface of Streptococcus gordonii. Infect Immun (2000) 1.00
Distinct cytokine regulation by cholera toxin and type II heat-labile toxins involves differential regulation of CD40 ligand on CD4(+) T cells. Infect Immun (2001) 1.00
Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells. Infect Immun (1999) 0.99
Heat-labile enterotoxins as adjuvants or anti-inflammatory agents. Immunol Invest (2010) 0.99
Native and mutant forms of cholera toxin and heat-labile enterotoxin effectively enhance protective efficacy of live attenuated and heat-killed Shigella vaccines. Infect Immun (1999) 0.92
Intranasal immunization with recombinant Ascaris suum 14-kilodalton antigen coupled with cholera toxin B subunit induces protective immunity to A. suum infection in mice. Infect Immun (2001) 0.90
Zonula occludens toxin is a powerful mucosal adjuvant for intranasally delivered antigens. Infect Immun (1999) 0.89
Pathogenicity and immune response measured in mice following intranasal challenge with enterotoxigenic Escherichia coli strains H10407 and B7A. Infect Immun (2003) 0.88
Nontoxic Shiga toxin derivatives from Escherichia coli possess adjuvant activity for the augmentation of antigen-specific immune responses via dendritic cell activation. Infect Immun (2005) 0.86
Zonula occludens toxin acts as an adjuvant through different mucosal routes and induces protective immune responses. Infect Immun (2003) 0.86
Inhibition of class II major histocompatibility complex antigen processing by Escherichia coli heat-labile enterotoxin requires an enzymatically active A subunit. Infect Immun (1998) 0.86
Concomitant enterotoxigenic Escherichia coli infection induces increased immune responses to Vibrio cholerae O1 antigens in patients with cholera in Bangladesh. Infect Immun (2010) 0.86
Incorporation of membrane-anchored flagellin or Escherichia coli heat-labile enterotoxin B subunit enhances the immunogenicity of rabies virus-like particles in mice and dogs. Front Microbiol (2015) 0.86
The identification of plant lectins with mucosal adjuvant activity. Immunology (2001) 0.84
Mucosal adjuvant activity of oligomannose-coated liposomes for nasal immunization. Glycoconj J (2009) 0.84
Dendritic cell-targeting DNA-based mucosal adjuvants for the development of mucosal vaccines. Expert Rev Vaccines (2009) 0.84
Enhanced mucosal and systemic immune responses to intestinal reovirus infection in beta2-microglobulin-deficient mice. J Virol (1997) 0.83
Facilitated intranasal induction of mucosal and systemic immunity to mutans streptococcal glucosyltransferase peptide vaccines. Infect Immun (2001) 0.82
Mucosal immunogenicity and adjuvant activity of the recombinant A subunit of the Escherichia coli heat-labile enterotoxin. Immunology (1999) 0.81
Mucosal delivery of bacterial antigens and CpG oligonucleotides formulated in biphasic lipid vesicles in pigs. AAPS J (2005) 0.79
Evaluation of the adjuvant effect of Escherichia coli heat-labile enterotoxin mutant (LTK63) on the systemic immune responses to intranasally co-administered measles virus nucleoprotein. Part I: antibody responses. Afr Health Sci (2001) 0.78
An efficient mRNA-dependent translation system from reticulocyte lysates. Eur J Biochem (1976) 46.42
Biology, immunology, and cariogenicity of Streptococcus mutans. Microbiol Rev (1980) 13.40
A prokaryotic-like mode of cytoplasmic eukaryotic ribosome binding to the initiation codon during internal translation initiation of hepatitis C and classical swine fever virus RNAs. Genes Dev (1998) 7.72
Preparation and use of nuclease-treated rabbit reticulocyte lysates for the translation of eukaryotic messenger RNA. Methods Enzymol (1983) 7.38
Prevention of prolonged labour. Br Med J (1969) 7.37
Isolation and characterization of homogeneous heat-labile enterotoxins with high specific activity from Escherichia coli cultures. Infect Immun (1979) 7.21
Phosphorylation of initiation factor elF-2 and the control of reticulocyte protein synthesis. Cell (1977) 6.22
Levels of seven urinary phthalate metabolites in a human reference population. Environ Health Perspect (2000) 5.63
Epidemic Yersinia enterocolitica infection due to contaminated chocolate milk. N Engl J Med (1978) 5.39
Terminology: nomenclature of mucosa-associated lymphoid tissue. Mucosal Immunol (2008) 5.28
In vitro translation of poliovirus RNA: utilization of internal initiation sites in reticulocyte lysate. J Virol (1984) 4.54
Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response. Adv Immunol (1987) 4.53
Unique features of internal initiation of hepatitis C virus RNA translation. EMBO J (1995) 4.44
Nonuniform probability of glutamate release at a hippocampal synapse. Science (1993) 4.23
Studies on the nature of polysomes. Biochem J (1964) 4.18
Vibrio cholerae adherence and colonization in experimental cholera: electron microscopic studies. Infect Immun (1976) 4.03
The mucosal immune system: from fundamental concepts to vaccine development. Vaccine (1992) 3.99
Immunological cross-reactivity between a heat-labile enterotoxin(s) of Escherichia coli and subunits of Vibrio cholerae enterotoxin. Infect Immun (1978) 3.95
Initiation of encephalomyocarditis virus RNA translation: the authentic initiation site is not selected by a scanning mechanism. EMBO J (1990) 3.92
Demonstration of shared and unique immunological determinants in enterotoxins from Vibrio cholerae and Escherichia coli. Infect Immun (1978) 3.80
A bactericidal effect for human lactoferrin. Science (1977) 3.73
Iodine nutrition in the United States. Trends and public health implications: iodine excretion data from National Health and Nutrition Examination Surveys I and III (1971-1974 and 1988-1994) J Clin Endocrinol Metab (1998) 3.69
Properties of homogeneous heat-labile enterotoxin from Escherichia coli. Infect Immun (1980) 3.36
Interleukins and IgA synthesis. Human and murine interleukin 6 induce high rate IgA secretion in IgA-committed B cells. J Exp Med (1989) 3.28
Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun (1995) 3.22
Subunit number and arrangement in Escherichia coli heat-labile enterotoxin. Infect Immun (1981) 3.15
Channel kinetics determine the time course of NMDA receptor-mediated synaptic currents. Nature (1990) 3.14
Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol (2001) 3.05
Life and death in the cytoplasm: messages from the 3' end. Curr Opin Genet Dev (1997) 3.01
Hypospadias trends in two US surveillance systems. Pediatrics (1997) 2.99
Lead toxicity in the 21st century: will we still be treating it? Pediatrics (1992) 2.95
Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J Immunol (1995) 2.87
The characteristics of inhibition of protein synthesis by double-stranded ribonucleic acid in reticulocyte lysates. J Biol Chem (1975) 2.84
A detailed kinetic analysis of the in vitro synthesis and processing of encephalomyocarditis virus products. Virology (1986) 2.82
Initiation of protein synthesis: evidence for messenger RNA-independent binding of methionyl-transfer RNA to the 40 S ribosomal subunit. J Mol Biol (1973) 2.80
Ingestion of Streptococcus mutans induces secretory immunoglobulin A and caries immunity. Science (1976) 2.78
Diversity revealed by a novel family of cadherins expressed in neurons at a synaptic complex. Neuron (1998) 2.73
Poliovirus protein 3CD is the active protease for processing of the precursor protein P1 in vitro. J Gen Virol (1988) 2.71
Plasmid specifying total degradation of 3-chlorobenzoate by a modified ortho pathway. J Bacteriol (1981) 2.66
Selective induction of an immune response in human external secretions by ingestion of bacterial antigen. J Clin Invest (1978) 2.64
Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. J Exp Med (1993) 2.62
Six Arabidopsis thaliana homologues of the human respiratory burst oxidase (gp91phox). Plant J (1998) 2.59
unr, a cellular cytoplasmic RNA-binding protein with five cold-shock domains, is required for internal initiation of translation of human rhinovirus RNA. Genes Dev (1999) 2.59
Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol (1998) 2.52
The involvement of a spliceosome component in internal initiation of human rhinovirus RNA translation. J Gen Virol (1993) 2.51
Initiation of translation of human rhinovirus RNA: mapping the internal ribosome entry site. Virology (1992) 2.47
Internal initiation of translation of hepatitis C virus RNA: the ribosome entry site is at the authentic initiation codon. RNA (1996) 2.45
Oral immunization with a recombinant bacterial antigen produced in transgenic plants. Science (1995) 2.44
Control of protein synthesis in reticulocyte lysates by haemin. Nat New Biol (1973) 2.39
Direct measurement of specific membrane capacitance in neurons. Biophys J (2000) 2.39
IgA antibody-producing cells in peripheral blood after antigen ingestion: evidence for a common mucosal immune system in humans. Proc Natl Acad Sci U S A (1987) 2.37
Difference in susceptibility to gram-negative urinary tract infection between C3H/HeJ and C3H/HeN mice. Infect Immun (1984) 2.35
Regulation of mucosal and systemic antibody responses by T helper cell subsets, macrophages, and derived cytokines following oral immunization with live recombinant Salmonella. J Immunol (1996) 2.30
Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. Diabetologia (2005) 2.21
Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nat Med (1998) 2.20
On the fidelity of mRNA translation in the nuclease-treated rabbit reticulocyte lysate system. Nucleic Acids Res (1989) 2.17
Screening for age-related macular degeneration using nonstereo digital fundus photographs. Eye (Lond) (2006) 2.13
Molecular characterization of a surface protein antigen gene from serotype c Streptococcus mutans, implicated in dental caries. Mol Microbiol (1989) 2.11
The primary role of lymphoreticular cells in the mediation of host responses to bacterial endotoxim. J Infect Dis (1980) 2.11
Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat Med (2001) 2.10
Translation of encephalomyocarditis virus RNA: parameters influencing the selection of the internal initiation site. EMBO J (1994) 2.08
A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc Natl Acad Sci U S A (1997) 2.07
Cloning of a surface protein antigen gene from serotype c Streptococcus mutans. Mol Microbiol (1989) 2.07
Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol (2000) 2.06
Active management of labour and cephalopelvic disproportion. J Obstet Gynaecol Br Commonw (1970) 2.06
An enzymatic method for preparation of dissociated murine Peyer's patch cells enriched for macrophages. J Immunol Methods (1982) 2.06
Immunobiology of dental caries: microbial aspects and local immunity. Annu Rev Microbiol (1981) 2.04
Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigens. Clin Microbiol Rev (1992) 2.02
Virulence of Streptococcus mutans: a sensitive method for evaluating cariogenicity in young gnotobiotic rats. Infect Immun (1975) 2.00
Differential alternative splicing activity of isoforms of polypyrimidine tract binding protein (PTB). RNA (2001) 1.98
The role of anxiety sensitivity in the pathogenesis of panic: prospective evaluation of spontaneous panic attacks during acute stress. J Abnorm Psychol (1997) 1.98
The immediate downstream codon strongly influences the efficiency of utilization of eukaryotic translation initiation codons. EMBO J (1994) 1.93
Accessory cells in murine Peyer's patch. I. Identification and enrichment of a functional dendritic cell. J Exp Med (1983) 1.92
Efficient initiation of mammalian mRNA translation at a CUG codon. Nucleic Acids Res (1989) 1.90
Production and properties of bacteriocins (mutacins) from Streptococcus mutans. Arch Oral Biol (1975) 1.89
Mucosal adjuvants. Vaccine (2005) 1.86
Effect of sucrose in culture media on the location of glucosyltransferase of Streptococcus mutans and cell adherence to glass surfaces. Infect Immun (1978) 1.86
Naturally occurring secretory immunoglobulin A antibodies to Streptococcus mutans in human colostrum and saliva. Infect Immun (1976) 1.85
Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming. Eur J Immunol (2000) 1.85
Prospective evaluation of anxiety sensitivity in the pathogenesis of panic: replication and extension. J Abnorm Psychol (1999) 1.84
Recombinant murine IL-5 induces high rate IgA synthesis in cycling IgA-positive Peyer's patch B cells. J Immunol (1988) 1.80
Mechanisms for induction of acquired host immunity by neutrophil peptide defensins. Proc Natl Acad Sci U S A (1999) 1.79
Optimizing oral vaccines: induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant. Infect Immun (1993) 1.78